drugset / Trial / NCT03590652
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
Phase 2
Terminated
23 enrolled
University of California, San Diego
Celgene Corporation · collabJanssen, LP · collabTakeda · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.
Timeline
- Start
- 2018-10-17
- Primary completion
- 2025-07-02
- Completion
- 2025-07-02
Outcome
Outcome not reported
Stopped: “The trial met its primary endpoint.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab Hyaluronidase-fihj | Unknown | 1800 mg | Subcutaneous |
| Subject | Dexamethasone | Small molecule | 20 mg | Oral |
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Ixazomib | Unknown | 4 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 4 mg | Oral |